v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 5,105,611 $ 5,353,392
Advances on research and development contract services 78,015 147,017
Prepaid insurance 23,230 49,224
Other prepaid expenses and current assets 27,840 10,380
Total current assets 5,234,696 5,560,013
Total assets 5,234,696 5,560,013
Current liabilities:    
Accounts payable and accrued expenses, including $43,895 and $46,982 to related parties at September 30, 2023 and December 31, 2022, respectively 221,171 229,764
Research and development contract liabilities 90,565 165,022
Total current liabilities 311,736 394,786
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares and 1,664,706 shares at September 30, 2023 and December 31, 2022, respectively 225 166
Additional paid-in capital 48,872,208 45,059,760
Accumulated deficit (47,449,473) (43,394,699)
Total stockholders’ equity 4,922,960 5,165,227
Total liabilities and stockholders’ equity $ 5,234,696 $ 5,560,013

Source